T. Rowe Price Associates’s Black Diamond Therapeutics BDTX Stock Holding History

T. Rowe Price Associates’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73K	Buy	+39,276	New	+$96.1K	﹤0.01%	3177
2025 Q2	–	Sell	-14,182	Closed	-$22K	–	3070
2025 Q1	$22K	Hold	14,182	–	–	﹤0.01%	2999
2024 Q4	$31K	Sell	14,182 -365,762	-96%	-$1.05M	﹤0.01%	2975
2024 Q3	$1.65M	Sell	379,944 -433,122	-53%	-$2.36M	﹤0.01%	1728
2024 Q2	$3.79M	Buy	+813,066	New	+$4.36M	﹤0.01%	1305
2020 Q4	–	Sell	-27,028	Closed	-$817K	–	2671
2020 Q3	$817K	Buy	+27,028	New	+$823K	﹤0.01%	1897

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

T. Rowe Price Associates's BDTX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 39,276 shares worth $73K. The stake represents ﹤0.01% of the portfolio and ranks #3177 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in BDTX as recently as Q1 2025.

T. Rowe Price Associates first reported a position in BDTX in Q3 2020 and has held it in 6 quarters since. The position peaked at $3.79M in Q2 2024. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

T. Rowe Price Associates held 39,276 shares of Black Diamond Therapeutics worth $73K as of Q2 2026.
Black Diamond Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
Black Diamond Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3177 holding.
T. Rowe Price Associates first reported a position in Black Diamond Therapeutics in Q3 2020 and has held it in 6 quarters since.
T. Rowe Price Associates's Black Diamond Therapeutics position peaked at $3.79M in Q2 2024.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.